Mitomycin C in Combination with Vinorelbine in Anthracycline- and/or Taxane-Pretreated Patients with Metastatic Breast CancerSchippert C. · Warm M. · Blohmer J.-U. · du Bois A. · Lück H.-J.
aKlinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, bBrustzentrum am Krankenhaus Köln-Holweide, Köln, cFrauenheilkunde und Geburtshilfe und Brustzentrum-City, St. Gertrauden Krankenhaus, Berlin, dKlinik für Gynäkologie & gynäkologische Onkologie, Kliniken Essen Mitte, Essen, eGynäkologisch-onkologische Praxis Hannover, Germany
Background: Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity. Mitomycin C (MMC) and vinorelbine (VNR) are suitable candidates for combination therapy in the second-/third-line treatment of MBC. This study evaluates the safety and efficacy of an MMC/VNR combination chemotherapy in pretreated patients with MBC. Patients and Methods: In a phase II trial, patients with anthracycline-and/or taxane-pretreated MBC were treated with MMC 8 mg/m2 (day 1) and VNR 25 mg/m2 (days 1 and 8) every 4 weeks for up to 6 cycles or until disease progression. Results: In 51 eligible patients, 13 (26%) partial remissions (PRs), 20 (39%) stable diseases (SDs) and 18 (35%) progressive diseases (PDs) were observed. The median progression-free survival (PFS) was 5.0 months. The main grade 3/4 toxicities were neutrocytopenia (41%), granulocytopenia (37%), and thrombocytopenia (4%). Other hematological and non-hematological toxicities were mostly mild. Conclusion: The combination of MMC and VNR is an effective and relatively well-tolerated regimen for anthracycline- and/or taxane-pretreated patients with MBC and is suitable for outpatient therapy.
Prof. Dr. med. Hans-Joachim Lück
Gynäkologisch-onkologische Praxis Hannover
Pelikanplatz 23, 30177 Hannover, Germany
Tel. +49 511 655528-0, Fax -98
Published online: August 13, 2012
Number of Print Pages : 2
Onkologie (International Journal for Cancer Research and Treatment)
Vol. 35, No. 9, Year 2012 (Cover Date: September 2012)
Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)
For additional information: http://www.karger.com/ONK